Co-Authors
This is a "connection" page, showing publications co-authored by SUNIL KRISHNAN and BRUCE MINSKY.
Connection Strength
1.511
-
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453.
Score: 0.211
-
Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiother Oncol. 2019 04; 133:54-61.
Score: 0.166
-
Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):323-332.
Score: 0.143
-
Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS One. 2016; 11(6):e0156910.
Score: 0.139
-
Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):755-65.
Score: 0.134
-
Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. J Hepatocell Carcinoma. 2021; 8:57-69.
Score: 0.048
-
Pathologic Response and Postoperative Complications After Short-course Radiation Therapy and Chemotherapy for Patients With Rectal Adenocarcinoma. Clin Colorectal Cancer. 2020 06; 19(2):116-122.
Score: 0.045
-
IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer. Adv Radiat Oncol. 2020 May-Jun; 5(3):369-376.
Score: 0.044
-
Assessment of setup uncertainty in hypofractionated liver radiation therapy with a breath-hold technique using automatic image registration-based image guidance. Radiat Oncol. 2019 Aug 30; 14(1):154.
Score: 0.043
-
Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies. Clin Transl Radiat Oncol. 2019 Nov; 19:59-65.
Score: 0.043
-
Corrigendum to "Imaging predictors of treatment outcomes in rectal cancer: An overview" [Crit. Rev. Oncol./Hematol. 129, (September) (2018), 153-162]. Crit Rev Oncol Hematol. 2019 02; 134:71.
Score: 0.041
-
Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 2018 10; 7(10):4880-4892.
Score: 0.040
-
Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):595-600.
Score: 0.040
-
Imaging predictors of treatment outcomes in rectal cancer: An overview. Crit Rev Oncol Hematol. 2018 Sep; 129:153-162.
Score: 0.040
-
Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer. 2018 04 15; 124(8):1701-1709.
Score: 0.039
-
Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 2018 07; 128(1):154-160.
Score: 0.038
-
Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. J Gastrointest Oncol. 2017 Dec; 8(6):990-997.
Score: 0.038
-
Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus. Clin Transl Radiat Oncol. 2017 Jun; 4:39-45.
Score: 0.037
-
Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. Am J Clin Oncol. 2017 Jun; 40(3):277-282.
Score: 0.037
-
Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. Am J Clin Oncol. 2017 Apr; 40(2):163-166.
Score: 0.037
-
Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. Radiother Oncol. 2017 01; 122(1):146-151.
Score: 0.036
-
Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg. 2017 01; 21(1):164-174.
Score: 0.036
-
Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. J Gastrointest Surg. 2016 12; 20(12):1975-1985.
Score: 0.035